上皮性卵巢癌：概述
Epithelial ovarian cancer: An overview.
作者信息
Desai Arpita, Xu Jingyao, Aysola Kartik, Qin Yunlong, Okoli Chika, Hariprasad Ravipati, Chinemerem Ugorji, Gates Candace, Reddy Avinash, Danner Omar, Franklin Geary, Ngozi Anachebe, Cantuaria Guilherme, Singh Karan, Grizzle William, Landen Charles, Partridge Edward E, Rice Valerie Montgomery, Reddy E Shyam P, Rao Veena N
机构信息
Department of Internal Medicine, University of Buffalo, Erie County Medical Center, Buffalo, NY 14215, United States.
Department of OB/GYN, Cancer Biology Program, Morehouse School of Medicine, Georgia Cancer Center for Excellence, Grady Health System, Atlanta, GA 30303, United States.
出版信息
World J Transl Med. 2014 Apr 12;3(1):1-8. doi: 10.5528/wjtm.v3.i1.1.
Abstract
Ovarian cancer is the second most common gynecological cancer and the leading cause of death in the United States. In this article we review the diagnosis and current management of epithelial ovarian cancer which accounts for over 95 percent of the ovarian malignancies. We will present various theories about the potential origin of ovarian malignancies. We will discuss the genetic anomalies and syndromes that may cause ovarian cancers with emphasis on Breast cancer type 1/2 mutations. The pathology and pathogenesis of ovarian carcinoma will also be presented. Lastly, we provide a comprehensive overview of treatment strategies and staging of ovarian cancer, conclusions and future directions.
摘要
卵巢癌是美国第二常见的妇科癌症，也是导致死亡的主要原因。在本文中，我们回顾了上皮性卵巢癌的诊断和当前治疗方法，上皮性卵巢癌占卵巢恶性肿瘤的95%以上。我们将介绍关于卵巢恶性肿瘤潜在起源的各种理论。我们将讨论可能导致卵巢癌的基因异常和综合征，重点是乳腺癌1/2型突变。还将介绍卵巢癌的病理和发病机制。最后，我们全面概述了卵巢癌的治疗策略和分期、结论及未来方向。
相似文献
1
Epithelial ovarian cancer: An overview.上皮性卵巢癌：概述
World J Transl Med. 2014 Apr 12;3(1):1-8. doi: 10.5528/wjtm.v3.i1.1.
2
3
[Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].23例同时性双原发性妇科恶性肿瘤的临床分析
Zhonghua Fu Chan Ke Za Zhi. 2022 May 25;57(5):352-360. doi: 10.3760/cma.j.cn112141-20220214-00086.
4
Hereditary Gynecologic Cancer Syndromes - A Narrative Review.遗传性妇科癌症综合征——一篇综述
Onco Targets Ther. 2022 Apr 8;15:381-405. doi: 10.2147/OTT.S353054. eCollection 2022.
5
Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes.遗传性癌症综合征——诊断和管理基础：第 1 部分：乳腺癌-卵巢癌综合征。
Mayo Clin Proc. 2019 Jun;94(6):1084-1098. doi: 10.1016/j.mayocp.2019.02.017.
6
Low-grade epithelial ovarian cancer: what a radiologist should know.低度恶性上皮性卵巢癌：放射科医生应了解的内容。
Br J Radiol. 2019 Mar;92(1095):20180571. doi: 10.1259/bjr.20180571. Epub 2019 Jan 31.
7
Primary surgical management of ovarian cancer.卵巢癌的初次手术治疗
Methods Mol Med. 2001;39:75-87. doi: 10.1385/1-59259-071-3:75.
8
Role of the stem cell niche in the pathogenesis of epithelial ovarian cancers.干细胞微环境在上皮性卵巢癌发病机制中的作用。
Mol Cell Oncol. 2014 Oct 31;1(3):e963435. doi: 10.4161/23723548.2014.963435. eCollection 2014 Jul-Sep.
9
Ovarian surface epithelium: family history and early events in ovarian cancer.卵巢表面上皮：家族史与卵巢癌的早期事件
Reprod Biol Endocrinol. 2003 Oct 7;1:70. doi: 10.1186/1477-7827-1-70.
10
Epithelial ovarian cancer: prevention, diagnosis, and treatment.上皮性卵巢癌：预防、诊断与治疗
CA Cancer J Clin. 1999 Sep-Oct;49(5):297-320. doi: 10.3322/canjclin.49.5.297.
引用本文的文献
1
Predicting preoperative lymph node metastasis in patients with high-grade serous ovarian cancer by using intratumoral and peritumoral radiomics: a retrospective cohort study.利用肿瘤内和肿瘤周围的影像组学预测高级别浆液性卵巢癌患者术前淋巴结转移：一项回顾性队列研究
BMC Med Imaging. 2025 Aug 12;25(1):323. doi: 10.1186/s12880-025-01868-x.
2
The Role of Neutrophil Extracellular Traps (NETs) in the Pathogenesis of Ovarian Cancer: New Insight and Future Perspectives.中性粒细胞胞外诱捕网（NETs）在卵巢癌发病机制中的作用：新见解与未来展望
Mol Biotechnol. 2025 Jul 12. doi: 10.1007/s12033-025-01473-x.
3
Unraveling the Hippo pathway: YAP/TAZ as central players in cancer metastasis and drug resistance.解析河马通路：YAP/TAZ在癌症转移和耐药性中扮演核心角色。
EXCLI J. 2025 Jun 6;24:612-637. doi: 10.17179/excli2025-8351. eCollection 2025.
4
Targeted synthesis of a trimethoxyphenyltetrahydropyrimidine analogue designed as a DNA intercalator: , multi-spectroscopic, thermodynamic, and approaches.靶向合成一种设计为DNA嵌入剂的三甲氧基苯基四氢嘧啶类似物：多光谱、热力学和[具体方法未给出]方法。
RSC Adv. 2025 May 8;15(19):14946-14965. doi: 10.1039/d5ra02179k. eCollection 2025 May 6.
5
Cell-Free DNA (cfDNA) Regulates Metabolic Remodeling in the ES-2 Ovarian Carcinoma Cell Line, Influencing Cell Proliferation, Quiescence, and Chemoresistance in a Cell-of-Origin-Specific Manner.游离DNA（cfDNA）调节ES-2卵巢癌细胞系中的代谢重塑，以细胞起源特异性方式影响细胞增殖、静止和化疗耐药性。
Metabolites. 2025 Apr 2;15(4):244. doi: 10.3390/metabo15040244.
6
Factors associated with declining cytoreductive surgery in advanced epithelial ovarian cancer: a population-based study.晚期上皮性卵巢癌中与细胞减灭术减少相关的因素：一项基于人群的研究。
World J Surg Oncol. 2025 Apr 4;23(1):119. doi: 10.1186/s12957-025-03769-3.
7
Extracellular vesicle miRNAs from three-dimensional ovarian cancer in vitro models and their implication in overall cancer survival.来自三维卵巢癌体外模型的细胞外囊泡微小RNA及其在癌症总体生存中的意义。
Heliyon. 2025 Jan 23;11(4):e42188. doi: 10.1016/j.heliyon.2025.e42188. eCollection 2025 Feb 28.
8
Predicting Survival Outcomes for Patients with Ovarian Cancer Using National Cancer Registry Data from Taiwan: A Retrospective Cohort Study.利用台湾地区国家癌症登记数据预测卵巢癌患者的生存结局：一项回顾性队列研究。
Womens Health Rep (New Rochelle). 2025 Jan 21;6(1):90-101. doi: 10.1089/whr.2024.0166. eCollection 2025.
9
Clinical Profiles and Survival Outcomes of Patients With Relapsed Ovarian Cancer: A Single-Center Study.复发性卵巢癌患者的临床特征与生存结局：一项单中心研究
Cureus. 2024 Nov 29;16(11):e74724. doi: 10.7759/cureus.74724. eCollection 2024 Nov.
10
Protein kinase C iota promotes glycolysis via PI3K/AKT/mTOR signalling in high grade serous ovarian cancer.蛋白激酶 C 亚型通过 PI3K/AKT/mTOR 信号通路促进高级别浆液性卵巢癌的糖酵解。
Mol Biol Rep. 2024 Sep 14;51(1):983. doi: 10.1007/s11033-024-09918-3.
本文引用的文献
1
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.贝伐珠单抗联合化疗治疗铂耐药复发性卵巢癌：AURELIA 开放性随机 III 期试验。
J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17.
2
Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma.盆腔（卵巢、输卵管和原发性腹膜）浆液性癌的起源和发病机制。
Annu Rev Pathol. 2014;9:27-45. doi: 10.1146/annurev-pathol-020712-163949. Epub 2013 Aug 5.
3
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.自体裂解物脉冲树突状细胞疫苗接种，随后过继转移经疫苗激发的体外共刺激T细胞用于复发性卵巢癌治疗
Oncoimmunology. 2013 Jan 1;2(1):e22664. doi: 10.4161/onci.22664.
4
Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma.遗传性卵巢癌和两 compartment 肿瘤代谢：BRCA1 缺失的上皮细胞诱导过氧化氢产生，在肿瘤基质中驱动氧化应激和 NFκB 激活。
Cell Cycle. 2012 Nov 15;11(22):4152-66. doi: 10.4161/cc.22226. Epub 2012 Oct 9.
5
Comprehensive molecular portraits of human breast tumours.人类乳腺肿瘤的全面分子特征图谱。
Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.
6
BRCA1 proteins regulate growth of ovarian cancer cells by tethering Ubc9.BRCA1 蛋白通过连接 Ubc9 来调节卵巢癌细胞的生长。
Am J Cancer Res. 2012;2(5):540-8. Epub 2012 Aug 20.
7
Olaparib, PARP1 inhibitor in ovarian cancer.奥拉帕利，卵巢癌的 PARP1 抑制剂。
Expert Opin Investig Drugs. 2012 Oct;21(10):1575-84. doi: 10.1517/13543784.2012.707189. Epub 2012 Jul 13.
8
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.OCEANS：一项在铂敏感复发性上皮性卵巢癌、原发性腹膜癌或输卵管癌患者中进行的化疗联合或不联合贝伐珠单抗的随机、双盲、安慰剂对照 III 期试验。
J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23.
9
Cancer statistics, 2012.癌症统计数据，2012 年。
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
10
A phase 3 trial of bevacizumab in ovarian cancer.贝伐珠单抗治疗卵巢癌的 III 期临床试验。
N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799.
Zotero 插件